TW202345909A - 免疫原性mRNA遞送載體 - Google Patents

免疫原性mRNA遞送載體 Download PDF

Info

Publication number
TW202345909A
TW202345909A TW112104167A TW112104167A TW202345909A TW 202345909 A TW202345909 A TW 202345909A TW 112104167 A TW112104167 A TW 112104167A TW 112104167 A TW112104167 A TW 112104167A TW 202345909 A TW202345909 A TW 202345909A
Authority
TW
Taiwan
Prior art keywords
composition
lipid
lnp
antigen
mrna
Prior art date
Application number
TW112104167A
Other languages
English (en)
Chinese (zh)
Inventor
安德魯 N 康福思
艾蜜莉 A 戈瑟琳
Original Assignee
美商科納療法股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商科納療法股份有限公司 filed Critical 美商科納療法股份有限公司
Publication of TW202345909A publication Critical patent/TW202345909A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW112104167A 2022-02-07 2023-02-06 免疫原性mRNA遞送載體 TW202345909A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263307578P 2022-02-07 2022-02-07
US63/307,578 2022-02-07

Publications (1)

Publication Number Publication Date
TW202345909A true TW202345909A (zh) 2023-12-01

Family

ID=85640795

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112104167A TW202345909A (zh) 2022-02-07 2023-02-06 免疫原性mRNA遞送載體

Country Status (9)

Country Link
US (1) US20250134994A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475824A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506429A (cg-RX-API-DMAC7.html)
CN (1) CN118843455A (cg-RX-API-DMAC7.html)
AU (1) AU2023216364A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250781A1 (cg-RX-API-DMAC7.html)
IL (1) IL314720A (cg-RX-API-DMAC7.html)
TW (1) TW202345909A (cg-RX-API-DMAC7.html)
WO (1) WO2023150757A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118267481A (zh) * 2024-04-08 2024-07-02 浙江大学 一种环境适应性协同调控的mRNA纳米递送系统的构建与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
CN109692326A (zh) * 2017-10-23 2019-04-30 华中科技大学 一种蜂毒脂质纳米颗粒的应用
MX2023004371A (es) * 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
JP2024514026A (ja) * 2021-04-12 2024-03-27 コーナー セラピューティクス, インコーポレイテッド 哺乳類の樹状細胞の過剰活性化因子

Also Published As

Publication number Publication date
US20250134994A1 (en) 2025-05-01
IL314720A (en) 2024-10-01
CA3250781A1 (en) 2023-08-10
CN118843455A (zh) 2024-10-25
EP4475824A1 (en) 2024-12-18
WO2023150757A1 (en) 2023-08-10
JP2025506429A (ja) 2025-03-11
AU2023216364A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
US20240197869A1 (en) Hyperactivators of mammalian dendritic cells
JP2024514026A5 (cg-RX-API-DMAC7.html)
TW202402303A (zh) 編碼具持續性活性之環GMP-AMP合成酶之mRNA及用於彼等之脂質遞送載體
Zhou et al. A leucine derivate-adjuvanted LNP vaccine enhances antitumor immunity through mTOR activation and metabolic reprograming in dendritic cells
US20250134994A1 (en) Immunogenic mrna delivery vehicles
US20250127868A1 (en) Hyperactivating lipid nanoparticles
TW202400253A (zh) 編碼具持續性活性之環gmp-amp合成酶之核酸及用於彼等之免疫原性遞送載體
WO2024057892A1 (ja) 抗腫瘍免疫応答増強剤
JP2025505628A5 (cg-RX-API-DMAC7.html)
CN118922179A (zh) 超激活脂质纳米颗粒
CN120529901A (zh) 用于哺乳动物树突状细胞超活化的磷脂类似物
TW202502377A (zh) 旁觀者抗原增強之腫瘤細胞溶解物免疫原性
CN118215501A (zh) 哺乳动物树突细胞的超激活剂
WO2025221606A1 (en) Lipids for hyperactivation of mammalian dendritic cells
HK40125917A (en) Anti-tumor immune response enhancer
BR122024018908A2 (pt) Uso de um biomaterial e um inibidor de cox2, composições e kits